Articles tagged with Pancreatic Cancer
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
Researchers discuss advancements in pancreatic cancer detection using biomarkers, imaging techniques, and molecular diagnostics. Novel therapies targeting the tumor microenvironment and immune evasion mechanisms are explored to improve survival outcomes.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.
A Chinese Medical Journal study investigates the role of non-coding RNAs in pancreatic cancer, revealing how dysregulation of these molecules contributes to tumor growth and treatment resistance. The research highlights potential therapeutic targets for this devastating disease.
A new study from the University of California, Davis found that switching from a high-fat to a low-fat diet slowed precancerous changes in the pancreas, even after weight gain and precancerous changes began. Researchers observed normalized gut microbiome, gene expression, and intercellular communication after dietary change.
Scientists at UC San Francisco discovered how pancreatic cancer cells metastasize to the lungs or liver using the PCSK9 protein. PCSK9 controls cholesterol acquisition, with low levels favoring the liver and high levels supporting lung adaptation.
The Phase 1 study of EBC-129 has shown encouraging signs of efficacy in heavily pre-treated pancreatic ductal adenocarcinoma patients, with an overall response rate of 25% and disease control rate of 87.5%. The drug also demonstrated a manageable safety profile, with no major treatment-related adverse events.
Researchers at Ohio State University have developed blood tests to diagnose pancreatic cancer and predict treatment outcomes. Genetic information can also help predict breast cancer survival rates, while a new blood test may improve treatment response for patients with advanced sarcoma. These findings offer promising tools for early de...
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
The study found increasing incidence rates for five cancer types without corresponding increases in late-onset age groups. The greatest increases were seen in female breast cancer, colorectal cancer, kidney cancer, and uterine cancer.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A new study presents RMC-6236, a powerful inhibitor of RAS genes, showing promise in combination with other treatments. The study suggests that combining RMC-6236 with chemotherapy and targeted therapies could overcome therapy resistances and improve therapeutic outcomes in pancreatic cancer.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A new type of connective tissue cell has been discovered that can hold back the growth of pancreatic cancer. The interferon response cancer-associated fibroblasts (ifCAF) have opposite properties to other CAF cells, which stimulate tumor development. This discovery may lead to new treatments for pancreatic cancer.
Researchers developed DNA origami structures that selectively deliver fluorescent imaging agents to pancreatic cancer cells, enabling more accurate cancer imaging and selective chemotherapy delivery. The study also explored the use of origami-folded DNA molecules loaded with chemotherapy drugs for targeted delivery to cancer cells.
Researchers at Nagoya University found that patients with high-risk stigmata and invasive nodules in their pancreatic cysts had a significant impact on their survival. The presence of invasive nodules led to improved survival rates after surgery, while those without invasive nodules had favorable outcomes even without surgery.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
A study reveals that Galectin-1 protein, located in fibroblast nuclei, promotes tumor growth and resistance to treatment. The protein regulates gene expression at a specific level, activating KRAS, a key driver of uncontrolled growth and tumor aggressiveness.
Researchers have developed a new method to identify and classify pancreatic cancer cell subtypes by analyzing sugar molecules on the surface of cells. This approach may lead to more precise diagnoses and better treatment options for patients.
Researchers found significant disparities in quality of care and outcomes for patients with metastatic pancreatic cancer. Patients with higher social vulnerability indices were less likely to receive guideline-concordant systemic therapy, palliative care, or survive over 12 months.
Researchers discovered that normal pancreatic cells can temporarily retain 'memory' of cancer-linked epigenetic marks, even in the absence of genetic mutations. This finding suggests a key role for epigenetic memory in cancer development and may explain increasing cancer rates in young people.
Scientists have found a way to effectively 'intercept' pancreatic cancer by targeting the KRAS and FGFR2 genes. This approach slows tumor formation and reduces the number of 'early versions' of cancer in the pancreas. Researchers believe this therapy could be a game-changer for patients with a family history of pancreatic cancer.
Researchers found that FGFR2 expression was higher in KRAS-mutated precancerous lesions and some KRAS-mutated PDAC tumors. Inactivation of FGFR2 delayed KRAS-mutated PDAC development in mice, suggesting a potential role for FGFR2 in driving cancer progression.
A new study led by the University of Michigan Rogel Cancer Center found that patients with three specific variants face no extra risk of dying from their cancer. The researchers used data from the Surveillance, Epidemiology and End Results programs in Georgia and California, looking at a total of about 78,000 patients with breast, colo...
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
Scientists have discovered a potential new treatment strategy for pancreatic cancer by identifying the molecule Neuropeptide Y (NPY) as a key driver of its spread. Blocking NPY's function has been shown to reduce cancer cell movement and metastatic outgrowth, potentially limiting disease progression.
A new type of RAS inhibitor, daraxonrasib (RMC-6236), has shown significant promise when combined with immunotherapy in preclinical models of pancreatic cancer. The study found that the treatment not only inhibited tumor growth but also reshaped the tumor microenvironment to make it more receptive to immunotherapy.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
The study found that Black patients have a higher prevalence of PD-L1 overexpression, TP53 mutations, and KRASG12R mutations compared to White patients. This could affect how their cancer progresses and responds to treatment.
Excessive alcohol consumption causes severe digestive problems, including liver damage, stomach disorders, and increased cancer risk. Chronic alcohol use can lead to conditions like cirrhosis, pancreatitis, and colorectal cancer.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
A new study suggests that chronic stress and an unhealthy diet may work together to fuel the early development of pancreatic cancer. Researchers found that both stress-related neurotransmitters and obesity-related hormones activate a protein called CREB, which is linked to cancer cell growth.
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.
Researchers identified co-occurring genetic alterations in colorectal and pancreatic cancers that contribute to resistance to KRAS G12C inhibitors. These mutations can lead to poor prognosis and chemotherapy resistance.
Amplified Sciences has received CLIA certification for its PanCystPro test, which helps risk stratify patients with pancreatic cystic lesions. The company plans to commercialize the test through an early access program and a clinical utility trial in 2025.
Researchers at Trinity College Dublin have discovered a biomarker panel that can accurately identify patients at risk of developing pancreatic cancer, offering new hope for early detection and improved treatment. The study uses a combination of blood and fluid analysis to distinguish between low- and high-risk patients.
Researchers discovered that pancreatic cancer reprograms nerve cells to promote tumor growth. Blocking nerve function inhibited cancer growth and increased sensitivity to certain therapies.
Researchers at Oregon Health & Science University have developed a new blood test called PAC-MANN, which can detect pancreatic cancer with 85% accuracy. The test uses a small blood sample to identify changes in protease activity, a key indicator of the most common and deadly form of pancreatic cancer.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
Researchers at UCSF describe how to curb MYC levels by disrupting the protein assembly line controlled by RBM42. Disrupting RBM42 in pancreatic cancer cells stopped them from growing, suggesting drugs could be developed to do the same for other fast-growing cancers.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
A novel approach transforms treatment for pancreatic cancer by repurposing WR-2721 to protect healthy tissue from radiation damage. Phase 1 and 2 clinical trials are underway to evaluate the safety and efficacy of the new therapy, which could add years of survival to patients.
A new approach to cancer therapy is being developed by inhibiting mechanotransduction, a process that regulates processes such as tumour progression and wound healing. The INTROPY project aims to validate the potential of six molecules in blocking this process, offering a new strategy for cancer treatment.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
A research team at Memorial Sloan Kettering Cancer Center has identified a novel molecular pathway leading to the formation of tertiary lymphoid structures (TLSs) in tumors. TLSs are immune cell clusters that can boost the local immune response and may be harnessed for immunotherapy treatments.
A recent study published in Cancer Letters reveals that the experimental test correctly identified 71% of pancreatic cancer samples compared to 44% by current gold-standard test. The new test detects two sugars produced by pancreatic cancer cells, reducing false negatives while maintaining low false positives.
Researchers have developed a way to detect circulating tumor cells in the bloodstream using biolasers, which can provide valuable information about the DNA organization inside cancer cells. The technique has been successfully tested on pancreatic and lung cancer patients, showing high accuracy rates of up to 99%.
Researchers at University of California San Diego have identified MICAL2 enzyme as a promising target for pancreatic cancer treatment. The study found that excessive production of the enzyme promotes tumor growth and spread in pancreatic ductal adenocarcinomas.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
A new study detects pre-malignant pancreatic lesions using Diffusion Tensor Imaging (DTI), a form of MRI, which could enable early diagnosis and effective therapies. The detection was successful in both transgenic mice and human samples, opening the way to non-invasive diagnostic tools for PanINs.
Researchers developed a deep learning model that classifies pancreatic cancer into molecular subtypes using histopathology images, achieving high accuracy and rapid turnaround time. The AI tool has the potential to improve patient outcomes by enabling timely and tailored treatment strategies.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A pioneering study of 192 Brazilian patients with pancreatic ductal adenocarcinoma identified genetic variants associated with the disease. The researchers found that 6.25% had pathogenic germline variants in genes predisposing to pancreatic cancer, and 13% had variants in genes associated with limited or previously unknown associations.